Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
182 hedge funds and large institutions have $1.41B invested in Array Biopharma Inc in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 28 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 61
0% more call options, than puts
Call options by funds: $24.3M | Put options by funds: $24.2M
3% less funds holding
Funds holding: 187 → 182 (-5)
5% less capital invested
Capital invested by funds: $1.49B → $1.41B (-$76.2M)
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$27.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$27M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$23.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.5M |
| 5 |
Morgan Stanley
New York
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.8M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$17.8M |
| 3 |
PC
PointState Capital
New York
|
-$17.7M |
| 4 |
Two Sigma Investments
New York
|
-$13.9M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$12.3M |
ARRY Hedge Fund Activity: Q2 2017 in Review
182 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2017, worth a combined $1.41B — down 5.1% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARRY and 24 opened new positions — a net loss of 4 holders — while 61 trimmed existing stakes and 70 added.
The largest buyer was Redmile Group, adding an estimated $27.2M. The largest seller was Fidelity Investments, cutting an estimated $38.8M.
- 182 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2017, down from 187 in Q1 2017.
- Funds reported $1.41B of Array Biopharma Inc stock for Q2 2017, down 5.1% quarter-over-quarter.
- 24 funds opened new Array Biopharma Inc positions in Q2 2017 and 28 closed out, a net change of -4 holders.
- The largest Array Biopharma Inc buyer in Q2 2017 was Redmile Group, an estimated $27.2M added.
- The largest Array Biopharma Inc seller in Q2 2017 was Fidelity Investments, an estimated $38.8M sold.
Based on aggregated 13F filings for Q2 2017.